Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 3 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

Results 1 - 20 of 58 : 1 2 3 Next »

Recs

0
Member Avatar marsuculix (43.93) Submitted: 3/23/2015 8:57:10 AM : Underperform Start Price: $2.50 AMRN Score: +2.96

not profitable yet!

Recs

0
Member Avatar vaderblue (< 20) Submitted: 3/13/2015 5:09:47 PM : Outperform Start Price: $3.28 AMRN Score: -27.26

After looking into the research on this BioTec I see growth and continuity

Recs

0
Member Avatar superstar (99.65) Submitted: 3/12/2015 11:18:31 AM : Outperform Start Price: $2.43 AMRN Score: -2.02

HC Wainwright, analyst with impressive track record over the last few years raised AMRN to BUY, with price target of $10. I agree with that assessment. AMRN now has plenty of cash through 2017, and I expect the Vacepa commercialization in China will greatly exceed expectations.

Recs

0
Member Avatar OklaBoston (64.41) Submitted: 2/26/2015 11:00:59 AM : Outperform Start Price: $1.55 AMRN Score: +55.73

Multiple senior officers made open market buys totaling over150,000 shares in November.

Last open market sale by senior officer was in October, 2012.

Recs

1
Member Avatar zzlangerhans (99.81) Submitted: 9/12/2014 10:37:14 AM : Outperform Start Price: $1.45 AMRN Score: +60.41

The "revocation of the revocation" trade in Amarin never made much sense to me. The FDA revoked the ANCHOR SPA for a clear reason - to allow a more orderly rejection of Vascepa for the ANCHOR indication, with a reduced risk of legal challenge. Why would they suddenly turn around and re-entangle themselves in a legal quagmire? Nevertheless, enough traders bought in to the idea for the stock to take a 22% hit this morning on news that the FDA had denied the company's final appeal of the SPA revocation.

I bought 5000 shares at 1.4 today, not because I think Amarin has great long-term prospects, but because I think the short-term reaction is slightly overdone. Momos came in and took the price too high, and now they're flooding out and dropping it too low. Of course, there's always the possibility that the market could use this event to reset the steady state price of Amarin lower in anticipation of the upcoming sNDA rejection. I have a terrible track record with Amarin on CAPS and in real life, but for some reason that isn't enough to keep me on the sidelines.

Recs

0
Member Avatar bottomfisherman (36.58) Submitted: 10/31/2013 4:07:55 PM : Underperform Start Price: $1.65 AMRN Score: -26.77

Soon to be found on the Pink Sheets in the near foreseeable future.

Recs

0
Member Avatar fatmoneyrz (99.24) Submitted: 10/30/2013 3:12:48 PM : Outperform Start Price: $2.36 AMRN Score: -17.54

This is probably going to zero, but I'll take a gamble on caps on the long side just for fun.

Recs

0
Member Avatar log81 (< 20) Submitted: 10/17/2013 11:59:22 PM : Underperform Start Price: $1.99 AMRN Score: -0.78

Ouch.

Recs

0
Member Avatar thefifth (< 20) Submitted: 10/15/2013 6:31:10 PM : Outperform Start Price: $2.07 AMRN Score: -5.54

current price is fearful vs. most likely outcome

Recs

1
Member Avatar Rilac (98.76) Submitted: 10/11/2013 4:49:00 PM : Outperform Start Price: $5.87 AMRN Score: -80.49

after perusing the brief documents for the adcom on the 16th, it seems as if the price movement for Amarin has been over exaggerated. i read nothing really abhorrent. nonetheless i took in a position before today's closing

Recs

0
Member Avatar ulanve (59.75) Submitted: 10/7/2013 12:10:43 AM : Outperform Start Price: $7.20 AMRN Score: -89.95

amrn

Recs

0
Member Avatar TerryHoodSr (80.11) Submitted: 7/31/2013 3:46:45 PM : Outperform Start Price: $2.03 AMRN Score: -3.29

potential

Recs

0
Member Avatar justin0820 (90.41) Submitted: 7/21/2013 10:02:20 PM : Outperform Start Price: $5.55 AMRN Score: -78.72

Sure, why not.

Recs

0
Member Avatar tftarpey (< 20) Submitted: 6/24/2013 2:13:29 PM : Outperform Start Price: $5.94 AMRN Score: -90.48

Everyone on the blogs hate it. A simple effective product that gets the job done. It works for high tri-gs and will do so for lower tri-gs. WAKE Up This is to simple for high tech Pharma.

Recs

1
Member Avatar chris293 (92.44) Submitted: 5/7/2013 2:50:43 AM : Underperform Start Price: $7.05 AMRN Score: +93.26

FDA approval for fish oil? What else is going on here, are they selling the good parts of the company for what?

Recs

0
Member Avatar mchedester (79.94) Submitted: 4/2/2013 7:26:24 AM : Outperform Start Price: $7.39 AMRN Score: -99.28

Oversold.

Recs

0
Member Avatar azinsd (< 20) Submitted: 3/30/2013 10:57:54 AM : Outperform Start Price: $7.42 AMRN Score: -99.42

Oh this is one is interesting - large consensus putting this one in 20s but for an NCE qualification that has little bearing on its performance - all star team in place to take this to finish line (much higher stock price) whatever it is

Recs

0
Member Avatar nijinksi (< 20) Submitted: 1/27/2013 3:42:49 PM : Outperform Start Price: $8.40 AMRN Score: -108.65

no real competitors in this field

Recs

0
Member Avatar SmartEquity (40.20) Submitted: 1/21/2013 9:08:25 AM : Outperform Start Price: $8.63 AMRN Score: -111.21

The market is discounting the commercialization potential of its star drug and not accounitng for the excellent team behind this launch.

Recs

0
Member Avatar cp15 (< 20) Submitted: 12/20/2012 10:52:51 AM : Outperform Start Price: $8.27 AMRN Score: -113.70

This Biotech in the middle of some mistakes has a lot potential because discovered and owned one of best medicaments that will be thrilling for many people's cardiovascular problems.

Results 1 - 20 of 58 : 1 2 3 Next »

Featured Broker Partners


Advertisement